Want to see CELU full AI Analyst Report?
Top Page
Celularity
(NASDAQ:CELU)
Select Model
Select Model
Rating:50Neutral
Price Target:
$1.50
▲(87.50% Upside)
Action:Reiterated
Date:09/29/26
Overall score reflects a balance between materially weak financial fundamentals (persistent losses, negative equity, and revenue decline) and somewhat improved trend factors (reduced cash burn) alongside moderately positive technical momentum. Corporate events are mixed—Nasdaq compliance improvements help, but filing delays, executive disruption, and insider financing underscore ongoing execution and capital-structure risk.
Positive Factors
Allogeneic therapy and platform model
Celularity combines an allogeneic placental-cell therapy pipeline with several potential commercialization routes, including collaborations, licensing, products, and eventual therapeutic sales. This platform approach could support recurring partnership economics and broaden revenue opportunities as candidates advance.
Negative Factors
Sharp revenue deterioration
The reversal from modest revenue growth to an approximately 35% decline signals weak and volatile commercial traction. Sustained contraction would reduce resources available for research and development, make operating leverage harder to achieve, and increase dependence on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Allogeneic therapy and platform model
Celularity combines an allogeneic placental-cell therapy pipeline with several potential commercialization routes, including collaborations, licensing, products, and eventual therapeutic sales. This platform approach could support recurring partnership economics and broaden revenue opportunities as candidates advance.
Read all positive factors
Celularity (CELU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$39.66M
Dividend YieldN/A
Average Volume (3M)8.22M
Price to Earnings (P/E)―
Beta (1Y)3.34
Revenue Growth-62.78%
EPS Growth-10.46%
CountryUS
Employees115
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.83
Shares Outstanding32,449,768
10 Day Avg. Volume177,581
30 Day Avg. Volume8,219,552
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Celularity Business Overview & Revenue Model
Company Description
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious condi...
How the Company Makes Money
Celularity’s publicly described revenue model is based on (1) advancing its placental-derived allogeneic cell therapy pipeline toward commercialization and (2) monetizing its platforms through collaborations and other commercial arrangements. Spec...
Celularity Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.97M | 26.55M | 54.22M | 22.77M | 17.98M | 21.34M |
| Gross Profit | 15.10M | 20.19M | 39.23M | 6.75M | -1.69M | 11.68M |
| EBITDA | -72.27M | -77.66M | -43.71M | -183.95M | -138.83M | -88.11M |
| Net Income | -71.28M | -91.80M | -57.89M | -196.29M | 14.19M | -100.12M |
Balance Sheet | ||||||
| Total Assets | 99.48M | 107.33M | 132.68M | 143.89M | 401.07M | 414.13M |
| Cash, Cash Equivalents and Short-Term Investments | 368.00K | 6.17M | 738.00K | 227.00K | 13.97M | 37.24M |
| Total Debt | 60.30M | 40.90M | 68.84M | 65.42M | 65.59M | 31.14M |
| Total Liabilities | 134.74M | 145.39M | 123.84M | 102.93M | 202.16M | 314.71M |
| Stockholders Equity | -35.26M | -38.06M | 8.84M | 40.96M | 198.90M | 99.42M |
Cash Flow | ||||||
| Free Cash Flow | -8.81M | -13.25M | -6.56M | -42.73M | -143.11M | -116.30M |
| Operating Cash Flow | -8.81M | -13.25M | -6.40M | -38.69M | -137.88M | -110.10M |
| Investing Cash Flow | 0.00 | 0.00 | 514.00K | -4.05M | -5.24M | -5.90M |
| Financing Cash Flow | 8.99M | 18.65M | 6.70M | 24.09M | 119.84M | 98.56M |
Celularity Technical Analysis
Positive
0.80
Price Trends
1.09
Positive
0.94
Positive
1.09
Positive
Market Momentum
0.04
Positive
53.23
Neutral
73.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Positive. The current price of 0.8 is below the 20-day moving average (MA) of 1.40, below the 50-day MA of 1.09, and below the 200-day MA of 1.09, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 53.23 is Neutral, neither overbought nor oversold. The STOCH value of 73.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CELU.
Celularity Risk Analysis
Celularity disclosed 76 risk factors in its most recent earnings report. Celularity reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celularity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $656.38M | -13.37 | -43.57% | ― | -66.63% | 57.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $39.66M | -0.48 | 239.78% | ― | -62.78% | -10.46% | |
46 Neutral | $8.72M | -0.22 | -536.78% | ― | ― | 22.10% | |
43 Neutral | $13.87M | -0.62 | -456.35% | ― | ― | 9.68% |
* Healthcare Sector Average
CELU
Celularity
1.35
-0.69
-33.82%
LTRN
Lantern Pharma
1.01
-3.11
-75.49%
STTK
Shattuck Labs
6.82
4.44
186.55%
FBLG
FibroBiologics, Inc.
1.30
-9.16
-87.57%
Celularity Corporate Events
Business Operations and StrategyExecutive/Board Changes
Celularity adds Naveen Jain amid strategic recapitalization
Positive
Sep 29, 2026
On Sept. 29, 2026, Celularity announced that Naveen Jain, founder and CEO of Viome Life Sciences, will join its Board of Directors following completion of required regulatory procedures. Jain, a serial entrepreneur whose ventures span InfoSpace, I...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Celularity Secures New Convertible Note Financing and Board Shift
Neutral
Sep 28, 2026
On September 23–24, 2026, Celularity Inc. entered into a securities purchase agreement enabling up to $25 million of senior secured convertible notes and accompanying warrants in two tranches and closed an initial $11.01 million tranche at a...
Delistings and Listing ChangesRegulatory Filings and Compliance
Celularity Restores Nasdaq Compliance on Key Listing Standards
Positive
Sep 14, 2026
On September 11, 2026, Celularity Inc. said it had regained compliance with Nasdaq’s minimum bid price requirement and the minimum market value of listed securities standard, leading Nasdaq to close both deficiency matters. The company still...
Business Operations and StrategyExecutive/Board Changes
Celularity Announces Sudden Exit of Chief Commercial Officer
Negative
Aug 7, 2026
On August 5, 2026, Celularity Inc. terminated the employment of Rick Gonzalez, who had been serving as the company’s Chief Commercial Officer, effective immediately. The abrupt departure of a key commercial executive may signal a shift in Ce...
Delistings and Listing ChangesRegulatory Filings and Compliance
Celularity Faces Nasdaq Listing Compliance Bid-Price Warning
Negative
Jul 29, 2026
On July 23, 2026, Celularity Inc. received notice from Nasdaq that its Class A common stock no longer meets the exchange’s minimum bid price requirement, after trading below $1.00 per share for 30 consecutive business days. The stock continu...
Executive/Board ChangesPrivate Placements and Financing
Celularity Secures Insider-Backed Short-Term Loan Facility
Negative
Jun 30, 2026
On June 29, 2026, Celularity entered into a secured $1 million short‑term loan agreement with the Philip Daniele Barach Family Trust, a related party lender affiliated with a significant shareholder, bearing 4.0% annual interest and maturin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.